Antileishmanial activity of the essential oil from bixa orellana

Phytotherapy Research

Volumn 28, Issue 5, 2014, Pages 753-758

  Monzote, Lianet ^a   García, Marley ^a   Scull, Ramón ^b   Cuellar, Armando ^b   Setzer, William N ^c  

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^b UNIVERSITY OF HAVANA   (Cuba)

^c University of Alabama in Huntsville   (United States)

Author keywords

Bixa orellana; essential oil composition; geranylgeraniol; ishwarane; Leishmania amazonensis

Indexed keywords

AMPHOTERICIN B; ESSENTIAL OIL; GERANYLGERANIOL; ISHWARANE; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BIXA ORELLANA; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG SCREENING; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA; MASS FRAGMENTOGRAPHY; MOUSE; NONHUMAN; PLANT SEED; SKIN LEISHMANIASIS; TREATMENT DURATION;

BIXA; BIXA ORELLANA; LEISHMANIA AMAZONENSIS; MUS; PROTOZOA;

BIXA ORELLANA; ESSENTIAL OIL COMPOSITION; GERANYLGERANIOL; ISHWARANE; LEISHMANIA AMAZONENSIS;

ANIMALS; ANTIPROTOZOAL AGENTS; BIXACEAE; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; OILS, VOLATILE; PLANT OILS; SEEDS;

EID: 84899484360     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5055     Document Type: Article

References (39)

1. Adams RP,. 2007. Identification of Essential Oil Components by Gas Chromatography / Mass Spectrometry, 4th Ed., Carol Stream, (ed.). Allured Publishing: Illinois.
2. Ahmed SB, Sghaier RM, Guesmi F, et al., 2011. Evaluation of antileishmanial, cytotoxic and antioxidant activities of essential oils extracted from plants issued from the leishmaniasis-endemic region of Sned (Tunisia). Nat Prod Res 25: 1195-1201.
3. Al-Abdely HM, Graybill JR, Loebenberg D, Melby PC,. 1999. Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniasis. Antimicrob Agents Chemother 43: 2910-2914.
4. Bastien P,. 2011. Leishmaniases control: what part for development and what part for research?. Clin Microbiol Infect 17: 1449-1450.
5. Blum J, Desjeux P, Schwartz E, Beck B, Hatz C,. 2004. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 53: 158-166.
6. Buffet PA, Sulahian A, Garin YJF, Nassar N, Derouin F,. 1995. Culture microtitration a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob Agents Chemother 39: 2167-2168.
7. Colmenares M, Kar S, Goldsmith-Pestana K, McMahon-Pratt D,. 2002. Mechanisms of pathogenesis: differences amongst Leishmania species. Trans R Soc Trop Med Hyg 96: S3-S7.
8. de Medeiros MD, da Silva AC, Citó AM, et al., 2011. In vitro antileishmanial activity and cytotoxicity of essential oil from Lippia sidoides Cham. Parasitol Int 60: 237-241.
9. Delorenzi JC, Attias M, Gattass CR, et al., 2001. Antileishmanial activity of an indole alkaloid from Peschiera australis. Antimicrobial Agents Chemother 45: 1349-1354.
10. Fournet A, Ferreira ME, Rojas A, Torres S, Fuentes S, Nakayama H,. 1996. In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of new world cutaneous leishmaniasis caused by Leishmania amazonensis. Antimicrob Agents Chemother 40: 2447-2451.
11. García M, Monzote L, Montalvo AM, Scull R,. 2011. Effect of Bixa orellana against Leishmania amazonensis. Forsch Komplementmed 18: 351-353.
12. García M, Monzote L,. 2010. Bixa orellana: properties and applications. RPMP 30: 25-35.
13. Govindachari TR, Mohamed PA, Parthasarathy PC,. 1970. Ishwarane and aristolochene, two sesquiterpene hydrocarbons from Aristolochia indica. Tetrahedron 26: 615-619.
14. Gupta J, Ali M, Pillai KK, Velasco-Negueruela A, Pérez-Alonso MJ, Contreras FG,. 1997. The occurrence of ishwarane and ishwarone in the root oil of Corallocarpus epigaeus Benth. ex Hook. F. J Essential Oil Res 9: 667-672.
15. Kedzierski L, Sakthianandeswaren A, Curtis JM, Andrews PC, Junk PC, Kedzierska K,. 2009. Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr Med Chem 16: 599-614.
16. Kedzierski L, Zhu Y, Handman E,. 2006. Leishmania vaccines: progress and problems. Parasitology 133: 87-112.
17. Lopes MV, Desoti VC, C AdE, Ueda-Nakamura T, Silva SO, Nakamura CV,. 2012. Mitochondria superoxide anion production contributes to geranylgeraniol-induced death in Leishmania amazonensis. Evid Based Complement Alternat Med 2012: 298320.
18. Machado M, Pires P, Dinis AM, et al., 2012. Monoterpenic aldehydes as potential anti-Leishmania agents: activity of Cymbopogon citratus and citral on L. infantum, L. tropica and L. major. Exp Parasitol 130: 223-231.
19. Menna-Barreto RFS, Laranja GAT, Silva MCC, et al., 2008. Anti-Trypanosoma cruzi activity of Pterodon pubescens seed oil: geranylgeraniol as the major bioactive component. Parasitol Res 103: 111-117.
20. Mohammadpour G, Marzony ET, Farahmand M,. 2012. Evaluation of the anti-Leishmania major activity of Satureja bakhtiarica essential oil in vitro. Nat Prod Commun 7: 133-136.
21. Monzote L, Alarcon O, Setzer WN,. 2012. Antiprotozoal activity of essential oils. Agriculturae Conspectus Scientificus 77: 167-175.
22. Monzote L, García M, Montalvo AM, Linares R, Scull R,. 2009. Effect of oral treatment with the essential oil from Chenopodium ambrosioides against cutaneous leishmaniasis in BALB/c mice, caused by Leishmania amazonensis. Res Complementary 16: 334-338.
23. Murray HW, Berman JD, Davies CR, Saravia NG,. 2005. Advances in leishmaniasis. Lancet 366: 1561-1577.
24. Oliveira VCS, Moura DMS, Lopes JAD, de Andrade PP, da Silva NH, Figueiredo RCBQ,. 2009. Effects of essential oils from Cymbopogon citratus (DC) Stapf., Lippia sidoides Cham., and Ocimum gratissimum L. on growth and ultrastructure of Leishmania chagasi promastigotes. Parasitol Res 104: 1053-1059.
25. Pillai AB, Xu W, Zhang O, Zhang K,. 2012. Sphingolipid degradation in Leishmania (Leishmania) amazonensis. PLoS Negl Trop Dis 6: e1944.
26. Pino JA, Correa MT,. 2003. Chemical composition of the essential oil from annatto (Bixa orellana L.) seeds. J Essential Oil Res 15: 66-67.
27. Raga DD, Espiritu RA, Shen CC, Ragasa CY,. 2011. A bioactive sesquiterpene from Bixa orellana. J Nat Med 65: 206-211.
28. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S,. 2007. Cutaneous leishmaniasis. Lancet Infect Dis 7: 581-596.
29. Sales D, Silva AL, de Almeida F, et al., 2012. Conventional therapy and promising plant-derived compounds against trypanosomatid parasites. Front Microbiol 3: 1-10.
30. Silveira FT, Lainson R, Corbett CE,. 2004. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: a review. Mem Inst Oswaldo Cruz 99: 239-251.
31. Sladowski D, Steer SJ, Clothier RH, Balls M,. 1993. An improved MTT assay. J Immunol Met 157: 203-207.
32. Teng LC, De Bardeleben JF,. 1971. A novel tetracyclic sesquiterpene from the oil of Orejuela of Cymbopetalum penduliforum. Experientia 27: 14-15.
33. Tiuman TS, Ueda-Nakamura T, Garcia Cortez DA, et al., 2005. Antileishmanial activity of parthenlide, a sesquiterpene lactone isolated from Tanacetum parthenium. Antimicrob Agents Chemother 49: 176-182.
34. Torres-Santos EC, Moreira DL, Kaplan MAC, Meirelles MN, Rossi-Bergmann B,. 1999. Selective effect of 2',6'-dihydroxy-4'-methoxychalcone isolated from Piper aduncum on Leishmania amazonensis. Antimicrob Agents Chemother 43: 1234-1241.
35. Ueda-Nakamura T, Mendonça-Filho RR, Morgado-Díaz JA, et al., 2006. Antileishmanial activity of Eugenol-rich essential oil from Ocimum gratissimum. Parasitol Int 55: 99-105.
36. Vannier-Santos MA, De Castro SL,. 2009. Electron microscopy in antiparasitic chemotherapy: a (close) view to a kill. Curr Drug Targ 10: 246-260.
37. Vila R, Milo B, Tomi F, Casanova J, Ferro EA, Can S,. 2001. Chemical composition of the essential oil from the leaves of Piper fulvescens, a plant traditionally used in Paraguay. J Ethnopharmacol 76: 105-107.
38. World Health Organization. 2009. Visceral leishmaniasis therapy: statement on the outcome of a meeting. Geneva: WHO. Available at: http://www.who.int/leishmaniasis/resources/Leish-VL- Therapy-statement.pdf (accessed August 16, 2010).
39. Yong YK, Zakaria ZA, Kadir AA, Somchit MN, Ee Cheng Lian G, Ahmad Z,. 2013. Chemical constituents and antihistamine activity of Bixa orellana leaf extract. BMC Complement Altern Med 13: 32.